Transcriptional Regulator ERG
"Transcriptional Regulator ERG" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A trans-activator and member of the erythroblast transformation-specific family of transcriptions factors that contain a characteristic ETS MOTIF. It is required for PLATELET CELL ADHESION to the subendothelium and associates with CHIMERIC ONCOGENE PROTEINS in PROSTATE CANCER; EWING'S SARCOMA; and ACUTE MYELOID LEUKEMIA.
| Descriptor ID |
D000071230
|
| MeSH Number(s) |
D12.776.260.755.100 D12.776.930.900.625
|
| Concept/Terms |
Transcriptional Regulator ERG- Transcriptional Regulator ERG
- Transforming Protein ERG
- V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog Protein
- V Ets Avian Erythroblastosis Virus E26 Oncogene Homolog Protein
- V-Ets Avian Erythroblastosis Virus E26 Oncogene Related Protein
- V Ets Avian Erythroblastosis Virus E26 Oncogene Related Protein
|
Below are MeSH descriptors whose meaning is more general than "Transcriptional Regulator ERG".
Below are MeSH descriptors whose meaning is more specific than "Transcriptional Regulator ERG".
This graph shows the total number of publications written about "Transcriptional Regulator ERG" by people in this website by year, and whether "Transcriptional Regulator ERG" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Transcriptional Regulator ERG" by people in Profiles.
-
Chimeric RNA Design Principles for RNA-Mediated Gene Fusion. Cells. 2022 03 16; 11(6).
-
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022 01; 601(7893):434-439.
-
Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology. 2020 Dec; 77(6):890-899.
-
Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2020 01; 80(1):65-73.
-
Comparative analysis of p16 expression among African American and European American prostate cancer patients. Prostate. 2019 08; 79(11):1274-1283.
-
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis. 2019 09; 22(3):438-445.
-
RNA-mediated gene fusion in mammalian cells. Proc Natl Acad Sci U S A. 2018 12 26; 115(52):E12295-E12304.
-
Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood. 2019 02 14; 133(7):724-729.
-
Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus. 2019 01; 5(1):54-61.
-
Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Cancer Res. 2017 12 01; 77(23):6524-6537.